Zydelig (idelalisib) — Medica
Chronic Lymphocytic Leukemia (CLL)
Initial criteria
- Patient is age ≥ 18 years
- Patient has tried at least one Bruton tyrosine kinase inhibitor (e.g., Imbruvica [ibrutinib], Brukinsa [zanubrutinib], Calquence [acalabrutinib], or Jaypirca [pirtobrutinib])
- Patient has tried at least one B-cell lymphoma 2 inhibitor (e.g., Venclexta [venetoclax])
Approval duration
1 year